Detalles de la búsqueda
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462870
2.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31730009
3.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res
; 29(14): 2714-2724, 2023 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37125965
4.
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Eur J Cancer
; 142: 18-28, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33212418
5.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Oncoimmunology
; 9(1): 1710389, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002308
6.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
J Immunother Cancer
; 7(1): 57, 2019 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30813970
Resultados
1 -
6
de 6
1
Próxima >
>>